The company said it updated its fiscal 2024 non-GAAP diluted EPS outlook to the high end of the $6.75 to $7.00 range. It cited favorability in Interest and Other and in Diluted Weighted Average Shares Outstanding as the drivers.

1. 01

   The company said it updated its fiscal 2024 non-GAAP diluted EPS outlook to the high end of the $6.75 to $7.00 range. It cited favorability in Interest and Other and in Diluted Weighted Average Shares Outstanding as the drivers.

2. 02

   Cardinal Health said it executed a new accelerated share repurchase program of $250M in Q2, and that continued strong cash flow generation left cash balances higher than expected.

3. 03

   The company said it now expects Medical segment profit for Q2 to be generally consistent with Q1 Medical segment profit, due to anticipated non-recurring adjustments. It said these adjustments do not affect its progress toward fiscal 26 targets.

4. 04

   Cardinal Health said that from January 1, 2024, it will operate with two reportable segments, Pharmaceutical and Specialty Solutions and GMPD, and will report Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics as Other. It said segment reporting under the new structure begins in Q3 fiscal 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.